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We have shown that transplanted bone marrow mononuclear cells (BM-MNC), which are a cell 37 
fraction rich in hematopoietic stem cells, can activate cerebral endothelial cells via gap junction 38 
mediated cell-cell interaction. In this article, we investigated such cell-cell interaction between 39 
mesenchymal stem cells (MSC) and cerebral endothelial cells. In contrast to BM-MNC, MSC 40 
we observed suppression of vascular endothelial growth factor (VEGF) uptake into endothelial 41 
cells and transfer of glucose from endothelial cells to MSC in vitro. The transfer of such a small 42 
molecule from MSC to vascular endothelium was subsequently confirmed in vivo, and was 43 
followed by suppressed activation of macrophage/microglia in stroke mice. The suppressive 44 
effect was absent by blockade of gap junction at MSC. Furthermore, gap junction mediated 45 
cell-cell interaction was observed between circulating white blood cells (WBC) and MSC. Our 46 
findings indicate that gap junction mediated cell-cell interaction is one of the major pathways 47 
for MSC-mediated suppression of inflammation in the brain following stroke and provides a 48 
novel strategy to maintain blood brain barrier in injured brain. Furthermore, our current results 49 
have the potential to provide a novel insight for other ongoing clinical trials which make use of 50 
MSC transplantation aiming to suppress excess inflammation, as well as other diseases such as 51 




Significance Statement  54 
We have demonstrated that gap junction mediated direct cell-cell interaction between 55 
transplanted mesenchymal stem cells (MSC) and cells of a recipient, including endothelial 56 
cell and circulating lymphocyte/monocyte, is one of the prominent pathways that suppress 57 
excessive inflammation following MSC transplantation. Our current results have the potential 58 
to provide novel insights in clinical trials that make use of MSC transplantation aiming to 59 
suppress excess inflammation. This is also relevant for other diseases including COVID-19 60 
(Coronavirus Disease 2019) which can cause fatal multiple organ failure due to vascular 61 





Mesenchymal stem cells (MSC), bone marrow mononuclear cells (BM-MNC) and neural stem 65 
cells are the major cell sources in cell-based therapies for stroke.1 However, the therapeutic 66 
mechanism of each therapy has been difficult to elucidate and this is likely to be a consequence 67 
of their complex composition. Therefore, significant research is underway to generate the next 68 
generation of cell-based therapies with improved characteristics. Recently, we demonstrated 69 
that direct cell-cell interaction between transplanted BM-MNC and cerebral endothelial cells 70 
via gap junction following cell transplantation is the prominent pathway for activation of 71 
regenerative processes after ischemia.2 Our findings revealed that BM-MNC activate injured 72 
endothelial cells by providing glucose via gap junction and accelerate VEGF uptake into 73 
endothelial cells followed by activation of angiogenesis at post stroke brain.2 74 
Similar to BM-MNC transplantation in stroke, a number of clinical trials of MSC 75 
transplantation in stroke are ongoing3 and multiple therapeutic mechanisms have been proposed, 76 
including the acceleration of angiogenesis,4 secretion of multiple cytokines and 77 
immunomodulation.5 However, the significance of the proposed mechanisms have largely been 78 
unclear. In this article, we report that MSC receive glucose from endothelial cells via gap 79 
junction and suppress VEGF uptake into endothelial cells followed by stabilization of the blood 80 
brain barrier in ischemic brain. This finding is essentially the converse of what was expected 81 
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with regards to cell-cell interaction between BM-MNC and endothelial cell. 82 
 83 
Materials and Methods 84 
The following study was approved by the Animal Care and Use Committee of Institute of 85 
Biomedical Research and Innovation and complies with the Guide for the Care and Use of 86 
Animals published by the Ministry of Education, Culture, Sports, Science and Technology in 87 
Japan. Experiments and results are reported according to the ARRIVE guidelines. A detailed 88 
methodological description is available in the supplement. 89 
Preparation of murine mesenchymal stem cells (MSC) 90 
Murine MSC obtained from C57BL/6 mice were purchased from Cyagen Biosciences (CA, 91 
USA). MSC were cultured with growth medium (OriCell Mouse MSC Growth Medium; 92 
Cyagen Biosciences) according to the manufacturer’s protocol. After thawing the freezing 93 
ampule, cold growth medium was added, and the cell suspension was centrifuged and the 94 
supernatant removed. The re-suspended cells in growth medium were seeded into a flask and 95 
incubated at 37ºC and 5% CO2. After reaching 80-90% confluence, cells were dissociated with 96 
0.25% Trypsin-EDTA (Thermo Fisher, MA, USA) and expanded. The growth medium was 97 
changed every three days. Cells in passage 9 were used for in vitro and in vivo experiments. 98 
Human vascular endothelial growth factor (hVEGF) uptake into human umbilical vein 99 
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endothelial cell (HUVEC) 100 
Human umbilical vein endothelial cells (HUVEC, Kurabo, Osaka, Japan) were cultured with 101 
medium, serum and growth factors (HuMedia-EB2, Kurabo) according to manufacturer’s 102 
protocol. HUVEC in passage 6 were used for all experiments. VEGF uptake was evaluated the 103 
methods as described elsewhere.2 Biotin-conjugated hVEGF (R&D Systems, Minneapolis, MN, 104 
USA) was incubated with streptavidin-conjugated APC (Thermo Fisher), at a 4:1 molar ratio 105 
for 10 minutes at room temperature. HUVEC were harvested and suspended in PBS containing 106 
1% fetal bovine serum (FBS, Thermo Fisher). MSC (1x105 cells) and APC-labeled hVEGF (10 107 
nM) was added to 1x105 HUVEC, and incubated for 3 hours at 37ºC. After co-incubation, cells 108 
were washed twice with PBS and stained with PE-conjugated anti-human CD31 antibody (BD 109 
Bioscience, MA, USA), FITC-conjugated anti-mouse Sca1 antibody (BD Bioscience, NJ, USA), 110 
and 7-AAD (BD Bioscience). The level of APC in HUVEC (CD31-positive, Sca1-negative and 111 
7AAD-negative) was evaluated using a FACS Calibur fluorescent cell sorter (BD Bioscience). 112 
To evaluate the relevance of gap junction mediated cell-cell interaction between HUVEC and 113 
MSC, MSC were incubated with the gap junction uncoupling agent 1-octanol (1 mM; Merck, 114 
NJ, USA) or gap junction-blocking carbenoxolone (CBX: 100 µM; Sigma, MO, USA) for 10 115 
minutes, and then washed twice with HuMedia-EB2 before co-culturing with HUVEC. 116 
Glucose concentration measurements 117 
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The glucose concentrations in MSC and HUVEC were measured using a glucose assay kit 118 
(Biovision, CA, USA) according to manufacturer’s protocol. Briefly, 2x105 MSC or 2x105 119 
HUVEC were incubated with HuMedia-EB2 (0.1% glucose) for 1 hour and washed twice with 120 
PBS before cell lysis. The glucose and protein concentration in cell lysates was evaluated by 121 
glucose assay kit. 122 
Glucose homologue transfer between HUVEC and MSC 123 
HUVEC and MSC were incubated with 25 µM 2-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-124 
2-deoxyglucose (2-NBDG; Peptide Institute, Osaka, Japan) in HuMedia-EB2 without glucose 125 
(Kurabo) for 1 hour at 37ºC. After washing the cells twice with PBS, 1x105 of HUVEC or MSC 126 
were co-cultured in 100 µl PBS for 3 hours at 37ºC. Mean fluorescence intensity in each cell 127 
type were measured using FACS. For control, 1x105 HUVEC or 1x105 MSC alone were 128 
cultured in 100 µl PBS for 3 hours at 37ºC. HUVEC and MSC without 2-NBDG were also 129 
prepared as 2-NBDG negative controls. 130 
Loading of low molecular weight fluorescence molecules in cytoplasm of MSC or white 131 
blood cells (WBC) 132 
MSC were incubated with 5 µM 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, 133 
acetoxymethyl ester (BCECF-AM; Dojindo, Kumamoto Japan) for 30 minutes at 37ºC 134 
according to manufacturer’s protocol. BCECF-AM is converted to 2',7'-bis-(2-carboxyethyl)-135 
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5-(6)-carboxyfluorescein (BCECF) in the cytoplasm and BCECF-loaded MSC were washed 136 
twice with PBS before use for in vitro and in vivo experiments. Murine blood samples were 137 
obtained following puncture of the left ventricle of 9 week old male C57BL/6 mice (Clea Japan, 138 
Tokyo, Japan) with heparin sodium 50 U/mL (Mochida Pharmaceutical, Tokyo, Japan) and red 139 
blood cells were lysed with red blood cell lysis buffer (BD Bioscience) according to the 140 
manufacture’s protocol. BCECF-loaded WBC was prepared by the same way with MSC. 1x106 141 
BCECF-loaded WBC were incubated with 1x105 BCECF-unloaded MSC for 2 hours and the 142 
transfer of BCECF from WBC to MSC via gap junction was evaluated by FACS2 without or 143 
with blockade of gap junction of MSC by 1-octanol as we described above. Cell populations 144 
(lymphocytes, monocytes and granulocytes) were characterized using FACS as described 145 
previously.6 146 
Induction of focal cerebral ischemia and injection of MSC 147 
A murine stroke model with excellent reproducibility that made use of 7-week-old male CB-17 148 
mice (C.B-17/Icr- +/+Jcl: Oriental yeast, Tokyo, Japan) was utilized as described previously.7 149 
Briefly, permanent focal cerebral ischemia was induced by permanent ligation and 150 
disconnection of the distal portion of the left middle cerebral artery (MCA) using bipolar 151 
forceps under 3% halothane inhalation anesthesia. During surgery, rectal temperature was 152 
monitored and controlled at 37.0±0.2ºC by a feedback-regulated heating pad. Cerebral blood 153 
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flow (CBF) in the MCA area was also monitored. Mice showing a ≥75% decrease in CBF 154 
immediately after MCA occlusion were used for in vivo experiments (success rate was 100%). 155 
The weight of animals was ~20-25 grams before surgery. Twenty four hours after induction of 156 
stroke, 5x105 MSC or heparinized HBSS were injected via a tail vein. 157 
Immunohistochemistry 158 
Mice were anesthetized using sodium pentobarbital and perfused transcardially with saline 159 
followed by 4% paraformaldehyde (PFA). The brain was carefully removed and cut into coronal 160 
sections (20 µm) using a vibratome (Leica, Wetzlar, Germany). Sections were immunostained 161 
with primary antibodies against CD31 (BD Pharmingen, CA, USA; 1:50), connexin 37 (Cloud-162 
Clone, TX, USA; 1:50), connexin 43 (Proteintech, IL, USA; 1:200) or DAPI (Thermo Fisher, 163 
1:1,000). Alexa 555-coupled antibody (Novus Biologicals, CO, USA) was used as the 164 
secondary antibody to visualize CD31. Alexa 647 (Novus Biologicals)-coupled secondary 165 
antibodies were used to detect connexin 37 or connexin 43 antibody. Anti-F4/80 (Serotec NC, 166 
USA; 1:50), was visualized by the 3,3'-diaminobenzidine (DAB) method and counterstained 167 
with Mayer’s Hematoxylin Solution (Wako, Osaka, Japan). The number of F4/80+ cells in 168 
0.25mm2 were counted in a blinded manner. 169 
For in vitro analysis of BCECF transfer from MSC to HUVEC, BCECF-loaded MSC (1x104 170 
cells) were co-cultured with HUVEC (1x105 cells) for 1 hour. After co-culture, cells were fixed 171 
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with 4% PFA for 15 minutes and stained with anti-Sca-1 antibody (BD Pharmingen, 1:50) and 172 
vWF (Merck 1:500) for identification of MSC and HUVEC respectively.   173 
Data analysis 174 
Statistical comparisons among groups were determined using one-way analysis of variance 175 
(ANOVA). Where indicated, individual comparisons were performed using Student's t-test. In 176 
all experiments, the mean ± SD are reported. 177 
 178 
Results 179 
MSC suppress VEGF uptake into HUVEC through gap junction mediated cell-cell 180 
interaction 181 
VEGF is one of the most prominent pro-angiogenic factors.2 Cerebral endothelial cells are 182 
known to uptake VEGF followed by activation of angiogenesis with increased permeability of 183 
blood brain barrier.8 We previously showed that BM-MNC increase VEGF uptake into HUVEC 184 
via gap junction mediated cell-cell interaction.2 To investigate the analogous property of MSC, 185 
these were co-cultured with HUVEC and any changes in VEGF uptake into HUVEC were 186 
assessed. Surprisingly, a significant reduction of VEGF uptake into HUVEC was observed 187 
when co-cultured with MSC (Figure 1A). To evaluate the importance of gap junction channel 188 
of MSC, its 1-octanol or carbenoxolone9 mediated blockade was investigated. Our results show 189 
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that the blockade of gap junction of MSC are abolished when co-incubated with HUVEC. These 190 
findings indicate that MSC reduce VEGF uptake into HUVEC by gap junction-mediated cell-191 
cell interaction, in contrast to BM-MNC that increase VEGF uptake into HUVEC. 192 
Glucose concentration in MSC and HUVEC 193 
We previously showed that the glucose concentration in BM-MNC is significantly higher than 194 
in HUVEC and that the transfer of glucose from BM-MNC to endothelial cells is one of the 195 
triggers that activates angiogenesis in endothelial cells. To investigate the analogous property 196 
of MSC, the concentration of glucose in MSC and endothelial cells was compared in vitro. In 197 
marked contrast to our expectation, MSC were shown to contain approximately half the 198 
concentration of glucose when compared with HUVEC (Figure 1B). The transfer of uptaken 199 
glucose between HUVEC and MSC was evaluated using the fluorescence-positive glucose 200 
homologue 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose (2-NBDG)2. 201 
MSC and HUVEC was separately incubated with 2-NBDG and washed twice before co-culture. 202 
A significant decrease in 2-NBDG levels was observed in HUVEC when co-cultured with MSC 203 
(Figure 1C). To confirm the importance of gap junction mediated cell-cell interaction between 204 
HUVEC and MSC, the gap junction channel of MSC was blocked by 1-octanol or 205 
carbenoxolone, and co-incubated with HUVEC. As expected, blockade of the gap junction 206 
channel of MSC resulted in decreased 2-NBDG levels in these cells. In contrast, the levels of 207 
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2-NBDG in MSC were significantly increased when co-cultured with HUVEC (Figure 1D). 208 
These findings indicate that the glucose concentration in MSC is reduced, which contrasts to 209 
that of BM-MNC that increases glucose concentration of HUVEC via gap junction mediated 210 
cell-cell small molecule transfer. 211 
In vivo cell-cell interaction between transplanted MSC and endothelial cells through gap 212 
junction 213 
In our previous study, we demonstrated in vivo cell-cell interaction between transplanted BM-214 
MNC and endothelial cells through gap junction using BCECF-loaded BM-MNC2. To 215 
investigate the analogous property of MSC, BCECF-loaded MSC were transplanted 216 
intravenously into mice at 24 hours after MCA occlusion. Mice were sacrificed 10 minutes after 217 
MSC transplantation, and co-localization of gap junctions and transferred BCECF in 218 
endothelial cells was evaluated by fluorescence confocal microscopy. Transferred BCECF-219 
positive signals were observed in endothelial cells at 10 minutes after cell transplantation, 220 
mostly overlapping with connexin 37 or 43 (Figure 2A-D). As in the case of BM-MNC 221 
transplantation following stroke,2 transplanted MSC nor obstruction of cerebral vasculature by 222 
transplanted MSC were rarely observed in the stroke area. It is noteworthy that the expression 223 
of connexin 37 or 43 were observed in the cell membrane of endothelial cells which are adjacent 224 
to the transferred BCECF signal at nuclei/cytosol of the cells. These findings indicate direct 225 
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cell-cell interaction via gap junction between MSC and endothelial cells in vivo, and are 226 
analogous to the cell-cell interaction between BM-MNC and endothelial cells following stroke. 227 
To confirm BCECF-positive signal transfer from MSC to endothelial cells in vitro, BCECF-228 
loaded MSC were cultured with HUVEC and BCECF-positive HUVEC were observed (Figure 229 
2E). 230 
Blockade of gap junction channels of transplanted MSC abolishes anti-inflammatory 231 
effects of MSC in mice brain 232 
MSC are known to suppress inflammatory reactions following stroke, including 233 
macrophage/microglia activation in the affected brain.5 However, the mechanism of 234 
inflammatory suppression by MSC transplantation in ischemic brain has been disputed. To 235 
evaluate the contribution of gap junction mediated cell-cell interaction between transplanted 236 
MSC and endothelial cells on suppression of inflammatory reactions following stroke, the effect 237 
of MSC with or without gap junction channel blockade was investigated. The results show a 238 
significant reduction of macrophage/microglia activation (number of F4/80+ cells) at 72 hours 239 
after induction of stroke (Figure 3A), although the anti-inflammatory effect was absent when 240 
MSC were pre-treated with the gap junction blocker prior to transplantation (Figure 3B). These 241 
findings indicate the significance of the gap junction mediated cell-cell interaction between 242 
MSC and endothelial cells in vivo to suppress inflammatory reactions following stroke. 243 
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Cell-cell interaction between MSC and circulating WBC 244 
Circulating WBC are also known to express gap junction.10 To investigate direct cell-cell 245 
interaction between transplanted MSC and circulating WBC, transfer of small molecules from 246 
WBC to MSC was evaluated in vitro. As shown in Figure 4A, transfer of BCECF from WBC 247 
to MSC was observed and the transfer was inhibited by the blockade of gap junction. Analysis 248 
of WBC with or without co-culture with MSC revealed the level of BCECF was significantly 249 
decreased in lymphocyte and monocyte by co-culture with MSC (Figure 4B). These findings 250 
indicated the transplanted MSC affect circulating WBS along with injured endothelial cells in 251 
brain and major WBC that react with MSC are lymphocyte and monocyte.   252 
 253 
Discussion 254 
We have demonstrated that MSC decreases VEGF uptake into endothelial cells in vitro and 255 
suppress inflammation in vivo through gap junction mediated cell-cell interaction. Our findings 256 
indicate that gap junction-mediated signaling is one of the major pathways for MSC-mediated 257 
suppression of inflammation in the brain following stroke. 258 
A gap junction channel between two cells is composed of two connexin in each half of the cell 259 
pair and they allow the prompt movement of small molecules according to their concentration 260 
gradient between cells.11 In our previous study, we had shown BM-MNC increases VEGF 261 
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uptake into endothelial cells via gap junction mediated cell-cell interaction and transfer of 262 
glucose from BM-MNC to endothelial cells via gap junction triggers angiogenesis.2 Since one 263 
of the proposed therapeutic mechanisms of MSC transplantation for stroke had been 264 
acceleration of angiogenesis,4 we expected a similar therapeutic mechanism in MSC with BM-265 
MNC. However, the transfer of glucose from endothelial cells to MSC was observed in this 266 
study with decreased VEGF uptake into endothelial cells by gap junction-mediated cell-cell 267 
interaction. These findings indicate that the therapeutic mechanisms of MSC and BM-MNC 268 
would be significantly different (Figure 5A-B). 269 
Uptake of VEGF is one of the key signals for endothelial cells to activate angiogenesis and 270 
increase permeability of barrier function following increased inflammation in ischemic brain.12-271 
14 In contrast, suppression of VEGF uptake attenuates blood-brain barrier disruption.15 We have 272 
demonstrated that MSC suppressed VEGF uptake of endothelial cells in vitro and intravenous 273 
injection of MSC reduced inflammatory responses at peri-stroke area. Furthermore, inhibition 274 
of gap junction channel of MSC abolishes the effect of MSC in vitro and in vivo. These results 275 
indicate that transplanted MSC suppressed inflammatory response in brain by inhibiting VEGF 276 
uptake into cerebral endothelial cells via gap junction mediated cell-cell interaction. 277 
Pericytes are known to be one of the MSC16 that are important for the stabilization of the blood-278 
brain barrier.17 Pericytes and cerebral endothelial cells are connected via gap junction and their 279 
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dissociation after ischemia had been shown to increase permeability followed by activation of 280 
macrophages.17 These findings suggest that transplanted MSC can substitute the function of 281 
dissociated pericytes. 282 
We have demonstrated that small molecules can be transferred from circulating WBC to MSC 283 
via gap junction (Figure 5C). Our results also indicate that the major cell populations that react 284 
with MSC are lymphocytes and monocytes, but not granulocytes. Lymphocyte causes graft-285 
versus-host disease (GvHD) after allogenic hematopoietic stem cell transplantation18 and MSC 286 
transplantation is known to have a therapeutic effect in GvHD, although the mechanism is not 287 
fully understood.19 Activation of lymphocytes are known to be related to increased glucose level 288 
in lymphocytes20 and glucose is one of the major factors that are transferred via gap junction 289 
between cells.2 Our current results relating to the small molecule outflow from lymphocytes to 290 
MSC via gap junction provides a novel insight of MSC therapy for GvHD. MSC transplantation 291 
is also known to have a therapeutic potential for COVID-19, although this mechanism is not 292 
fully understood either.21 Fatal vascular deterioration caused by cytokine release syndrome has 293 
been shown to be critical COVID-19 patients22 and the major players of cytokine release 294 
syndrome caused by COVID-19 are monocytes, lymphocytes and endothelial cells.23 Our 295 
current data indicate that MSC have the potential to directly regulate monocyte, lymphocyte 296 
and endothelial cells via gap junction mediated cell-cell interaction. Although further studies 297 
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are required to reveal the full linkage between MSC, monocytes, lymphocytes and endothelial 298 
cells via gap junction mediated cell-cell interaction, extending our hypothesis to COVID-19, 299 
although speculative at present has the potential to provide a novel insight for new therapeutic 300 
strategy against the COVID-19 cytokine storm. 301 
In conclusion, our findings establish that gap junction mediated direct cell-cell interaction 302 
between transplanted MSC and cells of recipient, including endothelial cells and circulating 303 
lymphocyte/monocyte is highly significant. Furthermore, our current results have potential to 304 
provide a novel insight to other clinical trials that make use of MSC transplantation aiming to 305 
suppress excess inflammation, which are ongoing for various diseases including COVID-19.24  306 
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Figure Legends 370 
Figure 1. Decreased hVEGF uptake into HUVEC when co-cultured with MSC and glucose 371 
transfer between these cells 372 
(A) APC-labelled VEGF uptake in HUVEC was evaluated using FACS. The percentage of 373 
APC-positive HUVEC was significantly decreased when co-cultured with MSC. Blockade of 374 
gap junction of MSC by 1-octanol (OCT) or carbenoxolone (CBX) abolishes this effect. (B) 375 
Glucose concentration in HUVEC was higher than that in MSC in the steady state. (C) 376 
Decreased 2-NBDG levels was observed in HUVEC during co-culture with MSC. It is 377 
noteworthy that blockade of gap junction of MSC by 1-octanol (OCT) or carbenoxolone (CBX) 378 
abolishes this effect. (D) In contrast, the level of 2-NBDG in MSC was increased when co-379 
cultured with HUVEC. Blockade of gap junction of MSC by 1-octanol (OCT) or carbenoxolone 380 
(CBX) abolishes this effect. **p<0.01, (A, D), *p<0.05 (B, C). n=3 in each group (A-D). 381 
 382 
Figure 2. Localization of gap junction and transfer of BCECF in endothelial cells 383 
(A,B) Co-localization of connexin 37 (light blue) and transferred BCECF (green) was observed 384 
in cerebral endothelial cells (red) (A). Merged image with explanation (B). (C, D) Co-385 
localization of connexin 43 (light blue) and transferred BCECF (green) in endothelial cells (red) 386 
(C). Merged image with explanation (D). (E) After co-incubation with BCECF-loaded Sca-1 387 
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positive MSC (red), transferred BCECF (green) was observed at vWF-positive HUVEC (light 388 
blue). Scale bars: 5 µm (A,C), 1µm (B,D), 100µm (E). Arrow heads indicate vWF-positive 389 
HUVEC (E). 390 
 391 
Figure 3. MSC suppress excess inflammation following stroke  392 
(A) Representative images of F4/80+ at 72 hours following stroke. MSC transplantation 393 
significantly suppressed the number of F4/80+ cells in the lesion border zone. (B) Application 394 
of a gap junction blocker (1-octanol) reduced the anti-inflammatory effect of MSC. *p<0.01 vs 395 
control, N=6 in each group (A, B). 396 
 397 
Figure 4. Gap junction mediated cell-cell interaction between circulating WBC and MSC 398 
(A) FACS analysis reveals transfer of low molecular weight substance (BCECF) from WBC to 399 
MSC. The transfer was inhibited by the blockade of gap junction of MSC by 1-octanol. (B) The 400 
level of BCECF was significantly decreased in monocytes and lymphocytes when co-incubated 401 
with MSC. **p<0.01 vs control (A). *p<0.05 and **p<0.01 vs MSC(-) control (B). n=4 (A) 402 
and n=3 (B) in each group. 403 
 404 
Figure 5. Schematic representation of our conclusions 405 
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(A) We have previously demonstrated that BM-MNC, which have a higher glucose 406 
concentration than endothelial cells, supply glucose to endothelia cell via gap junction followed 407 
by increased uptake of VEGF into endothelial cell with activation of angiogenesis. (B) In 408 
marked contrast, MSC have lower glucose concentration than endothelial cells. The reverse 409 
glucose flow suppresses VEGF uptake into endothelial cell followed by reducing the blood 410 
brain barrier permeability. (C) In addition to the interaction between MSC and endothelial cells, 411 
direct cell-cell interaction via gap junction was observed between MSC and circulating 412 
lymphocytes/monocytes. 413 
